Experimental antibody shows early promise for treatment of childhood tumor
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody. Four patients are still alive after more than two-and-a-half years and without additional treatment. Neuroblastoma is a cancer of the sympathetic nervous system. It is the most common cancer diagnosed in the first year of life and accounts for 7 to 10 percent of childhood cancers.
View full story